News

FDA approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) and the stand-alone monotherapy Seebri Neohaler (glycopyrrolate) – which is one component of Utibron Neohaler -- for patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

The FDA this week expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma - lowering the risk that melanoma will return following surgery.

The high cost of specialty medications requires an array of management techniques, according to a recent presentation at the Academy of Managed Care Pharmacy Nexus 2015. Read more.

For patients with diabetes or high blood cholesterol, greater medication adherence is associated with a greater likelihood that the patient will achieve target biometric A1c and low-density lipoprotein levels, respectively, according to a poster session presented at the Academy of Managed Care Pharmacy meeting.

A new online library or knowledge portal, the Type 2 Diabetes Genetics Beta, has been launched to provide open-access searching of genetic and clinical information on type 2 diabetes.

When two new treatments for idiopathic pulmonary fibrosis (IPF) were approved by FDA last year, there was not much data available on the drugs in patient populations.

The FDA approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy.